Login to Your Account



Topokine Doubles Down on Drug for Double Chins

By Catherine Shaffer
Staff Writer

Tuesday, November 19, 2013
Topokine Therapeutics Inc. has begun dosing in a Phase II trial of its XAF5 gel for reduction of excess submental fat, or double chin. The product is a formulation of XAF5, which reduces cellular lipid content and differentiation in adipocytes.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription